Larson Financial Group’s NRX Pharmaceuticals NRXP Stock Holding History

Larson Financial Group’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$90	Hold	22	–	–	﹤0.01%	3658
2026 Q1	$47	Hold	22	–	–	﹤0.01%	3549
2025 Q4	$60	Hold	22	–	–	﹤0.01%	3370
2025 Q3	$73	Hold	22	–	–	﹤0.01%	3339
2025 Q2	$72	Hold	22	–	–	﹤0.01%	3201
2025 Q1	$45	Hold	22	–	–	﹤0.01%	2996
2024 Q4	$48	Hold	22	–	–	﹤0.01%	2706
2024 Q3	$37	Hold	22	–	–	﹤0.01%	2654
2024 Q2	$54	Hold	22	–	–	﹤0.01%	2356
2024 Q1	$103	Hold	22	–	–	﹤0.01%	1703
2023 Q4	$100	Hold	22	–	–	﹤0.01%	1711
2023 Q3	$57	Hold	22	–	–	﹤0.01%	1676
2023 Q2	$105	Hold	22	–	–	﹤0.01%	1520
2023 Q1	$144	Hold	22	–	–	﹤0.01%	1482
2022 Q4	$242	Hold	22	–	–	﹤0.01%	1416
2022 Q3	$0	Hold	22	–	–	﹤0.01%	1367
2022 Q2	$0	Hold	22	–	–	﹤0.01%	1263
2022 Q1	$1K	Hold	22	–	–	﹤0.01%	983
2021 Q4	$1K	Hold	22	–	–	﹤0.01%	1026
2021 Q3	$2K	Buy	+22	New	+$2.86K	﹤0.01%	791

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Larson Financial Group's NRXP Position: Q2 2026 in Review

Larson Financial Group held its NRX Pharmaceuticals (NRXP) position steady in Q2 2026 at 22 shares worth $90. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

Larson Financial Group first reported a position in NRXP in Q3 2021 and has held it in 20 quarters since. The position peaked at $2K in Q3 2021. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

Larson Financial Group held 22 shares of NRX Pharmaceuticals worth $90 as of Q2 2026.
Larson Financial Group left its NRX Pharmaceuticals share count unchanged in Q2 2026.
NRX Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3658 holding.
Larson Financial Group first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
Larson Financial Group's NRX Pharmaceuticals position peaked at $2K in Q3 2021.
46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.